Daclatasvir + Famotidine = Precautionary

Effect on Concentration

Daclatasvir
Decrease
Applies within class?
No
Famotidine
No change
Applies within class?
No

Pharmacologic Effects

Effect
N/A
Applies within class?
No
Effect
N/A
Applies within class?
No

Interaction History

N/A

Last Updated 09-Jul-2018

Summary

The authors state that no dose adjustments are required. However, caution is warranted when utilizing this combination due to the wide CIs.

Sources

Study Design

*This interaction has not been formerly studied, but inferences are drawn from knowledge of the metabolic and transport pathways of each of the drugs.

Study Results

The manufacturer states that coadministration of daclatasvir with inhibitors or inducers of either CYP3A or P-gP may alter daclatasvir concentrations.

Study Conclusions

Inhibitors of P-gP or CYP3A may increase daclatasvir concentrations, while inducers of this enzyme and transport protein may decrease daclatasvir concentrations.

References

Garimella T, You X, Wang R, Huang SP, Kandoussi H, Biffano M, Eley T. A review of daclatasvir drug-drug interactions. Advances In Therapy. 2016; 11: 1867-1884.